Biocon Limited has reported its financial results for the year ended March 31, 2026. The company announced a final dividend of 10% (Rs. 0.50 per share) and detailed its strategic move to integrate Biocon Biologics Limited (BBL) as a wholly-owned subsidiary. Additionally, the Board approved a Long-Term Incentive Plan for employees, new leadership designations, and key board appointments to support its evolution into a Unified Global Biopharmaceutical Leader.
Financial Highlights
For the financial year ended March 31, 2026, Biocon achieved a consolidated revenue of Rs. 1,69,270 million. The company has recommended a final dividend of Rs. 0.50 per equity share, with the record date set for Friday, July 3, 2026. The dividend payout is scheduled to be completed on or before August 31, 2026.
Strategic Integration and Acquisitions
A core highlight of the board meeting was the approval to acquire the remaining ~2% of Biocon Biologics Limited (BBL). This move is part of a larger plan to fully integrate BBL and establish a Unified Global Biopharmaceutical Leader. The acquisition will be executed as a preferential issue of up to 87,92,317 equity shares of Biocon at an issue price of Rs. 376.16 per share, valued at approximately Rs. 330.73 Crores. The company also finalized the conversion of 1,125 Optionally Convertible Debentures (OCDs) and 1,06,86,044 Compulsorily Convertible Debentures (CCDs) into equity shares of BBL.
Leadership and Governance Changes
To strengthen its leadership team, the company appointed Dr. Anuj Goel as Chief Development Officer and Mr. Susheel Umesh as Chief Commercial Officer – Emerging Markets and Head of Global API & Global BD. Furthermore, the Board recommended the appointment of M/s. S. R. Batliboi & Associates LLP as the new Statutory Auditors for a five-year term, succeeding M/s. B S R & Co. LLP following the conclusion of the 48th Annual General Meeting.
Board Reconstitution
The company announced several changes to its Board of Directors to reflect its unified structure, including the re-appointment of Ms. Rekha Mehrotra Menon as an Independent Director. New appointments to the Board effective August 1, 2026, include Mr. Rajiv Malik, Mr. Daniel Bradbury, Mr. Peter Baron Piot, Mr. Arun Suresh Chandavarkar, and Ms. Nivruti Rai as Independent Directors, along with Mr. Thomas Jason Roberts as a Non-Executive Non-Independent Director.
Employee Incentive Plans
The Board approved the Biocon Unity Long Term Incentive Plan 2026. This comprehensive plan includes performance stock units, restricted stock units, and employee stock purchase options designed to align employee interests with long-term growth and innovation.
Source: BSE
